Is an active upper respiratory infection a contraindication to performing a transurethral resection of bladder tumor?

Is an Upper Respiratory Infection a Contraindication to TURBT?

An active upper respiratory infection is NOT an absolute contraindication to transurethral resection of bladder tumor (TURBT), but the procedure should be postponed when clinically feasible, particularly for lower-risk tumors, to minimize anesthetic complications and optimize patient safety.

Risk Stratification Determines Urgency

The decision to proceed or delay depends on the suspected tumor characteristics and clinical urgency:

Proceed Despite URI (High Priority Cases)

• Higher-risk non-muscle-invasive bladder cancer, especially with suspicion of T2 disease 1
• Macrohematuria requiring intervention 1
• Re-TURBT for incomplete initial resection 1
• Uncontrollable bleeding 1

Safe to Postpone (Lower Priority Cases)

• Presumed low-risk tumors 1
• Microhematuria without high-risk features 1
• Follow-up cystoscopy for low-risk NMIBC 1

Clinical Reasoning

The provided evidence does not specifically address URI as a contraindication to TURBT. However, standard anesthetic principles apply: active respiratory infections increase perioperative risks including bronchospasm, laryngospasm, hypoxemia, and postoperative pulmonary complications. These risks must be weighed against oncologic urgency.

Key Considerations:

Anesthetic Risk vs. Oncologic Risk:

• TURBT typically requires general or spinal anesthesia
• URI increases airway reactivity and respiratory complications during anesthesia
• Delaying high-risk bladder cancer resection can worsen prognosis, though evidence on specific delay thresholds is limited 1

Tumor Biology Matters:

• High-grade tumors and muscle-invasive disease should not be delayed unnecessarily
• Low-risk papillary tumors have lower recurrence rates and can safely wait 2-4 weeks for URI resolution

Infectious Complications:

• The baseline risk of postoperative UTI after TURBT is relatively low (2.3-3.4%) even without antimicrobial prophylaxis 2, 3
• URI does not directly increase urinary tract infection risk post-TURBT
• However, systemic infection risk may be elevated in immunocompromised states

Practical Algorithm

1. Assess tumor risk category (based on cystoscopy findings, prior pathology, presenting symptoms)

2. If high-risk features present (solid/sessile appearance, macrohematuria, suspected muscle invasion, recurrent high-grade disease):

   • Consult anesthesia regarding URI severity
   • Consider proceeding if URI is mild (no fever, minimal productive cough, normal oxygen saturation)
   • Optimize respiratory status with bronchodilators if needed
   • Ensure antimicrobial prophylaxis per guidelines 4

3. If low-risk features (small papillary lesion, microhematuria, low-grade history):

   • Postpone 2-4 weeks until URI resolves
   • This delay does not significantly impact oncologic outcomes for low-risk disease

4. If intermediate features:

   • Individualize based on URI severity, patient comorbidities (ASA score ≥3 increases infectious risk 2), and surgical scheduling constraints

Common Pitfalls to Avoid

• Do not routinely cancel all TURBTs for URI without risk stratification—high-risk tumors require timely intervention
• Do not proceed with elective TURBT in patients with active fever, productive cough, or respiratory distress—anesthetic complications outweigh benefits
• Do not confuse URI with urinary tract infection—the latter requires treatment before instrumentation when symptomatic 5
• Do not assume all delays are safe—muscle-invasive disease may progress, though specific evidence on delay impact is heterogeneous 1

The absence of specific guideline recommendations on URI and TURBT reflects that this is primarily an anesthetic safety decision rather than a urologic contraindication. Coordination with anesthesia and oncologic risk assessment should guide the final decision.